Tesamorelin research: how 1 drug reaches belly fat
Tesamorelin starts a brief release of growth hormone. This page follows each body step, then explains what the studies found.
How tesamorelin leads from gland to fat
Tesamorelin first acts on 1 pea-sized gland under the brain. The gland releases growth hormone in brief bursts [4][11]. In response, the liver makes IGF-1, a hormone that helps cells grow. The two hormones also help break down deep belly fat.
Studies of adults with HIV recorded lower amounts of deep belly fat. They also found less liver fat and more of the liver-made hormone. One study measured a 2.9% drop in liver fat [3].
Each finding below names who was studied. That keeps the limits clear for you.
How the growth gland responds to tesamorelin
The body response has four parts.
- Tesamorelin gives growth-gland cells a familiar message [4].
- The pea-sized gland adds growth hormone to the blood.
- Growth hormone reaches the liver.
- Next, the liver makes the related hormone named above.
Both hormones help break down stored belly fat [4]. Your body releases growth hormone in bursts. Tesamorelin keeps that up-and-down rhythm. It doesn't hold growth hormone high all day. One study tracked the drug and both hormones [11]. Growth hormone rose soon after the under-skin shot. The liver-made hormone stayed raised after that first rise ended.
A growth hormone shot works differently. The shot supplies the ready-made hormone.
How IGF-1 and blood sugar changed
The small test had five main facts.
- The study followed 13 healthy men for two weeks.
- The men received tesamorelin 2 mg per day.
- Their growth hormone rose during the night.
- Their liver-made hormone rose 181 micrograms per liter [4].
- Their fasting blood sugar did not clearly change.
One gram contains one million micrograms. The clear rise showed that the drug affected this blood test, not that it helped or harmed the men. Their bodies still answered insulin, which controls blood sugar. The largest HIV study also found the same hormone rose [1].
This small study doesn't settle long-term safety. It reports only those two weeks [4]. The hormone can help normal cells and cancer cells grow. Doctors watch its level, and active cancer rules out the drug. This study can't predict your long-term risk. The side effects and reasons to avoid tesamorelin page explains more.
What tesamorelin changed in liver fat
A study ran for 6 months with 50 adults who had HIV. Among them, 28 received tesamorelin and 22 received placebo. The study amount was 2 mg per day. On one scan slice, the drug group had 42 centimeters squared less deep belly fat. That is an area, not a weight or volume. Liver fat also fell [3].
In 2026, a review combined five studies. The review also found an average drop in liver fat [13].
Tests found changes in how liver cells made energy. Blood tests linked with inflammation also improved [3]. The paper didn't show whether the cell changes helped or harmed people by themselves. These adults had both HIV and fatty liver. The FDA hasn't approved tesamorelin for fatty liver outside HIV. The liver-fat research stays within that limit.
How fast tesamorelin falls in the blood
Blood tests show that tesamorelin drops soon after a shot. One study described the drop with a math model. The model's answer was 1,060 liters each hour [11]. This imaginary amount describes fast removal, not blood inside a person or fluid leaving the body.
By day 14, the model estimated about 13% more drug entered the blood than on day 1. The summary didn't state each blood-draw time. The paper called this an absorption finding, not harmful buildup or a benefit. Other papers put the halfway point at 26–38 minutes.
The hormone changes last after the drug level falls. Tesamorelin starts a short growth-hormone burst [11]. IGF-1 remains raised longer than the drug itself. The tesamorelin dosage page explains the study plan.
What later tesamorelin studies added
In 2021, CT scans showed denser remaining fat [9]. CT is a detailed X-ray picture. Researchers called this better fat quality, but they couldn't show better health.
In 2023, researchers rechecked a Phase 3 study. Everyone received tesamorelin 2 mg per day for 26 weeks. Deep belly fat and waist size fell in both groups. The groups differed only in neck fat. One group had a fat pad there. This fat can occur with HIV. It didn't change the belly-fat result [12].
In 2026, a review asked if tesamorelin might protect muscle during weight loss [14]. Five studies found a small rise in lean mass [13]. Lean mass includes muscle, organs, bone, and body water. The review relied on HIV studies. It didn't prove a benefit for ordinary weight loss.
None of these findings created another approved use.